JP2018512379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512379A5 JP2018512379A5 JP2017542004A JP2017542004A JP2018512379A5 JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5 JP 2017542004 A JP2017542004 A JP 2017542004A JP 2017542004 A JP2017542004 A JP 2017542004A JP 2018512379 A5 JP2018512379 A5 JP 2018512379A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021021535A JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114526P | 2015-02-10 | 2015-02-10 | |
| US62/114,526 | 2015-02-10 | ||
| PCT/US2016/017422 WO2016130726A1 (en) | 2015-02-10 | 2016-02-10 | Humanized anti-muc1* antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021535A Division JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512379A JP2018512379A (ja) | 2018-05-17 |
| JP2018512379A5 true JP2018512379A5 (https=) | 2019-03-14 |
| JP6895890B2 JP6895890B2 (ja) | 2021-06-30 |
Family
ID=56615670
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542004A Active JP6895890B2 (ja) | 2015-02-10 | 2016-02-10 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2021021535A Active JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A Pending JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A Pending JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021021535A Active JP7324789B2 (ja) | 2015-02-10 | 2021-02-15 | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP2023124894A Pending JP2023162180A (ja) | 2015-02-10 | 2023-07-31 | ヒト化抗ｍｕｃ１＊抗体 |
| JP2025091489A Pending JP2025148326A (ja) | 2015-02-10 | 2025-05-30 | ヒト化抗ｍｕｃ１＊抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11746159B2 (https=) |
| EP (1) | EP3256494A4 (https=) |
| JP (4) | JP6895890B2 (https=) |
| CN (2) | CN116199790A (https=) |
| AU (3) | AU2016219350A1 (https=) |
| CA (2) | CA3280347A1 (https=) |
| IL (1) | IL253909B (https=) |
| WO (1) | WO2016130726A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| AU2015243948B2 (en) | 2014-04-07 | 2020-10-15 | Minerva Biotechnologies Corporation | Anti-NME antibody |
| CN116199790A (zh) | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| CA3039797A1 (en) * | 2016-10-11 | 2018-04-19 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and use of cleavage enzyme |
| CN108003237B (zh) * | 2016-11-01 | 2023-03-10 | 中国科学院广州生物医药与健康研究院 | 高稳定性的人源化抗人cd3单链抗体及其制法和应用 |
| TWI780082B (zh) | 2016-11-18 | 2022-10-11 | 日商安斯泰來製藥股份有限公司 | 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段 |
| CN110300603B (zh) | 2017-02-14 | 2023-04-14 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| CN109790518A (zh) * | 2017-05-08 | 2019-05-21 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019094360A1 (en) * | 2017-11-07 | 2019-05-16 | The Board Of Regents Of The University Of Texas System | Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer |
| WO2019104306A1 (en) * | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| US20200405832A1 (en) * | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| BR112020023420A8 (pt) | 2018-05-17 | 2022-07-05 | Astellas Pharma Inc | Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante |
| SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
| JP7410143B2 (ja) | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| SG11201913540VA (en) * | 2019-03-15 | 2020-10-29 | Japanese Found For Cancer Res | Anti-Podoplanin Antibody |
| EP3966236A4 (en) * | 2019-05-07 | 2023-05-10 | The Board of Trustees of the Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
| US20220372098A1 (en) * | 2019-06-26 | 2022-11-24 | The Johns Hopkins University | Methods and materials for targeted expansion of immune effector cells |
| BR112021026389A2 (pt) * | 2019-06-26 | 2022-04-12 | Univ Johns Hopkins | Métodos e materiais para expansão direcionada de células t reguladoras |
| EP3999096A1 (en) * | 2019-07-19 | 2022-05-25 | Universiteit Antwerpen | Mucin isoforms in diseases characterized by barrier dysfunction |
| EP4161970A4 (en) * | 2020-06-08 | 2024-07-10 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES |
| AU2021286655A1 (en) | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| AU2021316042A1 (en) * | 2020-07-29 | 2023-03-30 | Minerva Biotechnologies Corporation | Anti-variable MUC1* antibodies and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| EP4408893A4 (en) * | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
| CN119317447A (zh) * | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2023220560A1 (en) * | 2022-05-09 | 2023-11-16 | Minerva Biotechnologies Corporation | Chimeric antigen receptor and il-18 receptor compositions and methods of use therein |
| US20240261406A1 (en) * | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| WO2024229126A2 (en) * | 2023-05-01 | 2024-11-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Mutant interleukin 15 expressing immune cells |
| WO2025250739A1 (en) * | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Chimeric antigen receptor with spacer domains derived from human igg |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5108933A (en) | 1988-09-16 | 1992-04-28 | Immunicon Corporation | Manipulation of colloids for facilitating magnetic separations |
| CA2003211A1 (en) | 1988-11-17 | 1990-05-17 | Pei-Xiang Xing | Monoclonal antibodies |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2069439A1 (en) | 1989-12-15 | 1991-06-16 | Susumu Iwasa | Monoclonal antibodies, their production and use |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| IL110464A0 (en) | 1994-07-26 | 1994-10-21 | Univ Ramot | Novel proteins for the diagnosis, imaging, and therapy of human cancer |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6127393A (en) | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US5767135A (en) | 1995-12-29 | 1998-06-16 | Fernandez-Pol; Jose Alberto | Antiviral agent |
| US20020136725A1 (en) | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| FR2746016B1 (fr) | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
| IL131447A0 (en) | 1997-02-18 | 2001-01-28 | Canji Inc | Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms |
| TWI242563B (en) | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| DE69941031D1 (de) | 1998-11-12 | 2009-08-06 | Novolytics Inc | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion |
| WO2000034783A1 (en) | 1998-12-08 | 2000-06-15 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists of the hdpxu17 receptor |
| AU3347900A (en) | 1999-01-23 | 2000-08-07 | Minerva Biotechnologies Corporation | Interaction of colloid-immobilized species with species on non-colloidal structures |
| AU3474100A (en) | 1999-01-25 | 2000-08-07 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| KR20090031957A (ko) | 1999-11-12 | 2009-03-30 | 더 존스 홉킨스 유니버시티 | 세포내 말로닐 ＣｏＡ의 수준을 증가시킴에 의한 암의 치료방법 |
| JP5165175B2 (ja) | 2000-09-11 | 2013-03-21 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１細胞外ドメインおよびそれから得られた癌治療組成物 |
| US20020156112A1 (en) | 2000-11-15 | 2002-10-24 | Bamdad R. Shoshana | Endostatin-like angiogenesis inhibition |
| EP2241887B1 (en) | 2000-11-27 | 2015-01-14 | Minerva Biotechnologies Corporation | Diagnostics, drug screening and treatment for cancer |
| JP2005508839A (ja) | 2001-03-29 | 2005-04-07 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ペプチドおよびｍｕｃ１タンパク質に対する抗体 |
| US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| EP2329822A1 (en) | 2001-09-05 | 2011-06-08 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| WO2003020280A2 (en) | 2001-09-05 | 2003-03-13 | Minerva Biotechnologies Corporation | Compositions and use thereof in the treatment of cancer |
| US6716627B2 (en) | 2001-12-20 | 2004-04-06 | Isis Pharmaceuticals, Inc. | Antisense modulation of mucin 1, transmembrane expression |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| WO2003089451A2 (en) | 2002-04-22 | 2003-10-30 | Dyax Corporation | Antibodies specific for mucin polypeptide |
| WO2003091447A2 (en) * | 2002-04-26 | 2003-11-06 | California Institute Of Technology | D1-1 nucleic acids, polypeptides and related methods |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060173171A1 (en) | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| WO2006028197A1 (ja) | 2004-09-06 | 2006-03-16 | Kirin Beer Kabushiki Kaisha | 抗a33抗体 |
| US20060147451A1 (en) | 2004-10-04 | 2006-07-06 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
| EP2526957A3 (en) | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
| EP1904531B1 (en) | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
| US7825092B2 (en) | 2006-08-08 | 2010-11-02 | University Of South Florida | Dendroaspis natriuretic peptide for treatment of cancer |
| US20090075926A1 (en) | 2006-12-06 | 2009-03-19 | Bamdad Cynthia C | Method for identifying and manipulating cells |
| US8420591B2 (en) | 2006-12-08 | 2013-04-16 | Dana-Farber Cancer Institute, Inc. | MUC1 and galectin-3 |
| US20100104626A1 (en) | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| EP2145901B1 (en) | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Recombinant anti-MUC1 antibodies |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| CN102272290B (zh) | 2008-10-09 | 2018-08-14 | 米纳瓦生物技术公司 | 用于在细胞中诱导多能性的方法 |
| CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| JP5549848B2 (ja) | 2008-12-25 | 2014-07-16 | 東ソー株式会社 | ルテニウム化合物、その製法及びそれを用いた成膜法 |
| MX2011013385A (es) | 2009-06-11 | 2012-05-29 | Minerva Biotechnologies Corp | Metodos para cultivar celulas madre y celulas progenitoras. |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| CN109456932A (zh) | 2011-10-17 | 2019-03-12 | 米纳瓦生物技术公司 | 用于干细胞增殖和诱导的培养基 |
| WO2013157102A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 |
| WO2014018679A2 (en) | 2012-07-24 | 2014-01-30 | Minerva Biotechnologies Corporation | Nme variant species expression and suppression |
| WO2014028668A2 (en) * | 2012-08-14 | 2014-02-20 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| WO2014055657A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9562110B2 (en) | 2012-11-21 | 2017-02-07 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody |
| CA2901893C (en) | 2013-02-20 | 2022-08-30 | Minerva Biotechnologies Corporation | Nme inhibitors and methods of using nme inhibitors |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| CN103880956B (zh) | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
| AU2015243948B2 (en) * | 2014-04-07 | 2020-10-15 | Minerva Biotechnologies Corporation | Anti-NME antibody |
| US20170051037A1 (en) * | 2014-05-02 | 2017-02-23 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| FI3169703T4 (fi) | 2014-07-16 | 2024-03-01 | Hinrich Abken | Kimeerinen antigeenireseptori ja sen käyttö |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN116199790A (zh) * | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| WO2017139906A1 (zh) | 2016-02-17 | 2017-08-24 | 王守国 | 一种等离子体加热器 |
| CA3039797A1 (en) * | 2016-10-11 | 2018-04-19 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and use of cleavage enzyme |
| WO2019104306A1 (en) * | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
-
2016
- 2016-02-10 CN CN202211743245.4A patent/CN116199790A/zh active Pending
- 2016-02-10 CN CN201680021263.8A patent/CN107660213B/zh active Active
- 2016-02-10 EP EP16749836.9A patent/EP3256494A4/en active Pending
- 2016-02-10 AU AU2016219350A patent/AU2016219350A1/en not_active Abandoned
- 2016-02-10 CA CA3280347A patent/CA3280347A1/en active Pending
- 2016-02-10 WO PCT/US2016/017422 patent/WO2016130726A1/en not_active Ceased
- 2016-02-10 CA CA2976089A patent/CA2976089C/en active Active
- 2016-02-10 US US15/549,942 patent/US11746159B2/en active Active
- 2016-02-10 JP JP2017542004A patent/JP6895890B2/ja active Active
-
2017
- 2017-08-08 IL IL253909A patent/IL253909B/en unknown
-
2021
- 2021-02-15 JP JP2021021535A patent/JP7324789B2/ja active Active
- 2021-10-21 AU AU2021254602A patent/AU2021254602B9/en active Active
-
2022
- 2022-08-04 US US17/817,515 patent/US11897967B2/en active Active
- 2022-08-04 US US17/817,525 patent/US12006371B2/en active Active
-
2023
- 2023-07-31 JP JP2023124894A patent/JP2023162180A/ja active Pending
-
2024
- 2024-04-24 US US18/644,795 patent/US20250026853A1/en active Pending
- 2024-09-18 AU AU2024219825A patent/AU2024219825A1/en active Pending
-
2025
- 2025-05-30 JP JP2025091489A patent/JP2025148326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512379A5 (https=) | ||
| Kaplon et al. | Antibodies to watch in 2022 | |
| JP2022512132A5 (https=) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2019535670A5 (https=) | ||
| JP2019536470A5 (https=) | ||
| HRP20240959T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1 | |
| JP2017535257A5 (https=) | ||
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| JP2021514973A5 (https=) | ||
| JP2018520993A5 (https=) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2015163068A5 (https=) | ||
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| JP2023551027A5 (https=) | ||
| JP2013198490A5 (https=) | ||
| JP2017149720A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2017500057A5 (https=) | ||
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| JP2020514277A5 (https=) | ||
| JP2016505546A5 (https=) | ||
| JP2021511387A5 (https=) |